Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
PRAX

PRAX - Praxis Precision Medicines Inc Stock Price, Fair Value and News

41.58USD+1.47 (+3.66%)Market Closed

Market Summary

PRAX
USD41.58+1.47
Market Closed
3.66%

PRAX Stock Price

View Fullscreen

PRAX RSI Chart

PRAX Valuation

Market Cap

711.3M

Price/Earnings (Trailing)

-5.67

Price/Sales (Trailing)

324.08

EV/EBITDA

-3.37

Price/Free Cashflow

-7.17

PRAX Price/Sales (Trailing)

PRAX Profitability

EBT Margin

-8365.97%

Return on Equity

-54.59%

Return on Assets

-50.07%

Free Cashflow Yield

-13.94%

PRAX Fundamentals

PRAX Revenue

Revenue (TTM)

2.2M

Rev. Growth (Yr)

-36.9%

Rev. Growth (Qtr)

-16.31%

PRAX Earnings

Earnings (TTM)

-125.4M

Earnings Growth (Yr)

-5.6%

Earnings Growth (Qtr)

-47.16%

Breaking Down PRAX Revenue

Last 7 days

6.7%

Last 30 days

-2.3%

Last 90 days

-22.8%

Trailing 12 Months

3515.7%

How does PRAX drawdown profile look like?

PRAX Financial Health

Current Ratio

11.27

PRAX Investor Care

Buy Backs (1Y)

72.45%

Diluted EPS (TTM)

-16.02

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20242.2M000
20231.3M1.7M2.1M2.4M
2022442.5K614.0K785.5K957.0K
2021205.5K00271.0K
2020166.5K00140.0K
2019000193.0K

Tracking the Latest Insider Buys and Sells of Praxis Precision Medicines Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
May 14, 2024
kelly timothy edwin
acquired
14,990
12.368
1,212
chief financial officer
May 14, 2024
souza marcio
acquired
42,496
12.368
3,436
chief executive officer
Feb 12, 2024
nemiroff alex
sold (taxes)
-2,277
44.65
-51.00
general counsel and secretary
Feb 12, 2024
mastrocola lauren
sold (taxes)
-2,143
44.65
-48.00
principal accounting officer
Feb 12, 2024
souza marcio
sold (taxes)
-12,100
44.65
-271
chief executive officer
Jan 07, 2024
souza marcio
sold (taxes)
-10,529
25.19
-418
chief executive officer
Jan 07, 2024
kelly timothy edwin
sold (taxes)
-3,501
25.19
-139
chief financial officer
Jan 07, 2024
nemiroff alex
sold (taxes)
-2,241
25.19
-89.00
general counsel and secretary

1–10 of 50

Which funds bought or sold PRAX recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
May 24, 2024
FARALLON CAPITAL MANAGEMENT LLC
new
-
3,051,000
3,051,000
0.01%
May 17, 2024
Ikarian Capital, LLC
reduced
-15.81
5,819,040
10,275,000
1.13%
May 16, 2024
FSA Wealth Management LLC
unchanged
-
1,281
1,281
-%
May 16, 2024
JANE STREET GROUP, LLC
added
345
2,636,330
2,871,970
-%
May 15, 2024
5AM Venture Management, LLC
new
-
20,746,800
20,746,800
4.64%
May 15, 2024
Logos Global Management LP
new
-
9,153,000
9,153,000
0.74%
May 15, 2024
Woodline Partners LP
new
-
1,663,590
1,663,590
0.01%
May 15, 2024
Soleus Capital Management, L.P.
new
-
2,274,090
2,274,090
0.17%
May 15, 2024
Altium Capital Management LP
new
-
4,765,660
4,765,660
1.89%
May 15, 2024
Atom Investors LP
added
16.08
1,458,360
2,127,580
0.26%

1–10 of 47

Are Funds Buying or Selling PRAX?

Are funds buying PRAX calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own PRAX
No. of Funds

Unveiling Praxis Precision Medicines Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
venrock healthcare capital partners iii, l.p.
8.9%
823,626
SC 13G/A
Feb 14, 2024
tri locum partners lp
2.8%
248,761
SC 13G/A
Feb 14, 2024
point72 asset management, l.p.
7.9%
692,252
SC 13G/A
Feb 14, 2024
cormorant asset management, lp
7.39%
633,345
SC 13G/A
Feb 14, 2024
verition fund management llc
8.0%
702,979
SC 13G
Feb 14, 2024
eventide asset management, llc
0.0%
0
SC 13G/A
Feb 14, 2024
pfm health sciences, lp
0.5%
6
SC 13G/A
Feb 13, 2024
avidity partners management lp
0%
0
SC 13G/A
Feb 13, 2024
huang james
0.0%
0
SC 13G/A
Feb 09, 2024
blackstone holdings i/ii gp l.l.c.
0.8%
70,273
SC 13G/A

Recent SEC filings of Praxis Precision Medicines Inc

View All Filings
Date Filed Form Type Document
Jun 10, 2024
S-8 POS
Employee Benefits Plan
Jun 06, 2024
4
Insider Trading
Jun 06, 2024
4
Insider Trading
Jun 06, 2024
4
Insider Trading
Jun 06, 2024
4
Insider Trading
Jun 06, 2024
4
Insider Trading
Jun 06, 2024
4
Insider Trading
Jun 06, 2024
8-K
Current Report
May 20, 2024
4
Insider Trading
May 20, 2024
4
Insider Trading

Peers (Alternatives to Praxis Precision Medicines Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
51.1B
6.8B
-18.41% 10.61%
-8.56
7.46
-64.45% -224.75%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
20.9B
2.0B
9.73% -16.82%
-63.08
10.46
75.20% 68.82%
15.9B
2.5B
9.61% -12.35%
77.45
6.44
13.74% 186.89%
14.2B
3.8B
8.63% 2.12%
19.04
3.77
8.58% 129.81%
MID-CAP
5.1B
107.9M
-6.63% 69.33%
-9.36
48.09
54.84% -28.31%
4.6B
524.1M
-12.71% -56.08%
-11.07
8.81
394.93% 39.61%
3.6B
251.0M
-0.36% -15.32%
-12.26
14.48
73.58% -86.73%
3.2B
240.7M
1.47% -28.24%
-6.7
12.77
-1.03% -213.92%
2.5B
813.8M
-3.10% -36.23%
-1.5K
3.11
56.43% 98.83%
2.0B
996.6M
-10.70% 95.81%
-4.94
1.98
-26.66% 65.49%
SMALL-CAP
1.8B
411.3M
-3.41% 18.74%
28.28
4.48
60.38% -34.49%
453.7M
881.7K
-5.58% 440.76%
-13.44
481.06
-77.61% 33.36%
209.4M
4.2M
-28.18% 49.63%
-1.68
50.33
-66.30% 48.24%
18.2M
2.1M
-6.22% 224.62%
-0.79
7.61
-13.45% 69.54%

Praxis Precision Medicines Inc News

Latest updates
MarketBeat18 hours ago
MarketBeat17 Jun 202410:48 pm

Praxis Precision Medicines Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q12020Q42020Q12019Q4
Revenue-16.3%431,000515,000468,000781,000683,000576,833470,667364,500258,333152,16746,00087,000128,000-
Operating Expenses49.4%42,317,00028,321,00025,984,00035,741,00038,774,00041,453,00044,290,00060,394,00068,849,00058,657,00027,419,00025,712,0008,469,000-
  S&GA Expenses54.4%15,333,0009,933,0008,724,00010,127,00013,270,00013,124,00013,851,00016,774,00016,197,00015,146,0009,490,0009,440,0001,601,000-
  R&D Expenses46.7%26,984,00018,388,00017,260,00025,614,00025,504,00028,329,00030,439,00043,620,00052,652,00043,511,00017,929,00016,272,0006,868,000-
EBITDA Margin-11.5%-83.46-74.87-88.32-107-137-191-233-271-376-615----
Income Taxes-----------5,000---11,000-
Earnings Before Taxes--------43,945,000---58,587,000-27,373,000-25,706,000-8,341,000-
EBT Margin-11.5%-83.66-75.04-88.52-107-138-191-233-272-377-616----
Net Income-47.2%-39,553,000-26,878,000-24,632,000-34,312,000-37,455,000-41,173,000-43,945,000-60,194,000-68,717,000-58,582,000-27,373,000-25,706,000-8,330,000-
Net Income Margin-13.4%-57.12-50.38-66.32-92.18-137-223-294-378-470-616----
Free Cashflow12.6%-20,907,000-23,911,000-23,215,000-31,214,000-32,846,000-28,806,000-44,964,000-57,319,000-54,398,000-45,388,000----
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32019Q4
Assets184.7%25088.0010713398.0011513718024029332435427930312048.00
  Current Assets149.5%21285.0010313094.0011113217623428731934827930211645.00
    Cash Equivalents86.9%15281.0010112481.0062.0062.0056.0078.0014016617613129711545.00
  Net PPE-19.0%0.001.001.001.001.001.001.001.001.001.001.000.000.000.000.000.00
Liabilities13.4%21.0018.0020.0028.0034.0039.0032.0042.0048.0042.0028.0020.0014.0016.0011.008.00
  Current Liabilities19.3%19.0016.0017.0024.0030.0034.0029.0039.0045.0038.0025.0016.0014.0016.0010.007.00
Shareholder's Equity229.7%23070.0087.0010664.0076.00105139191251296334266287--
  Retained Earnings-6.1%-693-653-627-602-568-530-489-445-385-316-258-213-176-149-123-81.01
  Additional Paid-In Capital27.6%923724714708633607595585577568554547443437--
Shares Outstanding50.8%13.009.001291294.003.0046.0046.0045.0045.0045.0040.00----
Float----147---104---761----
Cashflow (Last 12 Months)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q3
Cashflow From Operations12.6%-20,857-23,861-23,215-31,214-32,846-28,806-44,919-57,209-54,109-44,857-23,962-30,013-25,722-20,228-13,882-9,944-8,569--
  Share Based Compensation152.8%14,4755,7265,7635,7757,5936,3666,7307,6117,8866,1066,5215,4004,6663,826953285147--
Cashflow From Investing-182340.0%-91,220-50.00-5,00034,00022,59447,95534,890-8,55010,16913,550-24,229-140,010------
Cashflow From Financing4329.4%182,7574,126-69,67518,0705,3873,3655041,2097,71321299,385276202,064108,90623,446-30,000--
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

PRAX Income Statement

2024-03-31
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Income Statement [Abstract]  
Collaboration revenue$ 431$ 683
Operating expenses:  
Research and development26,98425,504
General and administrative15,33313,270
Total operating expenses42,31738,774
Loss from operations(41,886)(38,091)
Other income:  
Other income, net2,333636
Total other income2,333636
Net loss$ (39,553)$ (37,455)
Net loss per share attributable to common stockholders, basic (in dollars per share)[1]$ (2.84)$ (10.58)
Net loss per share attributable to common stockholders, diluted (in dollars per share)[1]$ (2.84)$ (10.58)
Weighted average common shares outstanding, basic (in shares)[1]13,904,3743,540,185
Weighted average common shares outstanding, diluted (in shares)[1]13,904,3743,540,185
[1]Results have been retroactively adjusted to reflect the 1-for-15 reverse stock split effected on November 28, 2023. See Note 2 for details.

PRAX Balance Sheet

2024-03-31
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 151,980$ 81,300
Marketable securities55,4360
Prepaid expenses and other current assets4,3883,580
Total current assets211,80484,880
Long-term marketable securities35,8730
Property and equipment, net476588
Operating lease right-of-use assets1,8402,064
Other non-current assets416416
Total assets250,40987,948
Current liabilities:  
Accounts payable9,4045,815
Accrued expenses6,9767,416
Operating lease liabilities1,1581,126
Current portion of deferred revenue1,2561,392
Total current liabilities18,79415,749
Long-term liabilities:  
Non-current portion of operating lease liabilities1,0661,369
Non-current portion of deferred revenue8661,161
Total liabilities20,72618,279
Commitments and contingencies (Note 6)
Stockholders’ equity:  
Preferred stock, $0.0001 par value; 10,000,000 shares authorized and no shares issued or outstanding as of March 31, 2024 and December 31, 202300
Common stock, $0.0001 par value; 150,000,000 shares authorized; 13,258,047 shares issued and outstanding as of March 31, 2024, and 8,791,877 shares issued and outstanding as of December 31, 20231313
Additional paid-in capital923,141723,577
Accumulated other comprehensive income30
Accumulated deficit(693,474)(653,921)
Total stockholders’ equity229,68369,669
Total liabilities and stockholders’ equity$ 250,409$ 87,948
PRAX
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase IIb clinical trial for the treatment of essential tremor, as well as in Phase II clinical trial to treat Parkinson's disease; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. Praxis Precision Medicines, Inc. was incorporated in 2015 and is based in Boston, Massachusetts.
 CEO
 WEBSITEhttps://praxismedicines.com
 INDUSTRYBiotechnology
 EMPLOYEES109

Praxis Precision Medicines Inc Frequently Asked Questions


What is the ticker symbol for Praxis Precision Medicines Inc? What does PRAX stand for in stocks?

PRAX is the stock ticker symbol of Praxis Precision Medicines Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Praxis Precision Medicines Inc (PRAX)?

As of Fri Jun 21 2024, market cap of Praxis Precision Medicines Inc is 711.35 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of PRAX stock?

You can check PRAX's fair value in chart for subscribers.

What is the fair value of PRAX stock?

You can check PRAX's fair value in chart for subscribers. The fair value of Praxis Precision Medicines Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Praxis Precision Medicines Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for PRAX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Praxis Precision Medicines Inc a good stock to buy?

The fair value guage provides a quick view whether PRAX is over valued or under valued. Whether Praxis Precision Medicines Inc is cheap or expensive depends on the assumptions which impact Praxis Precision Medicines Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PRAX.

What is Praxis Precision Medicines Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jun 21 2024, PRAX's PE ratio (Price to Earnings) is -5.67 and Price to Sales (PS) ratio is 324.08. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PRAX PE ratio will change depending on the future growth rate expectations of investors.